Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease and new therapies are desperately needed. Our previous work has shown that PDAC have an altered metabolism and that oncogenic Kras plays a key role in this metabolic reprogramming. Importantly, we have identified a novel, glutamine (Gln) -dependent pathway that is necessary for PDAC growth through the generation of NADPH for the maintenance of redox balance (referred to as the Gln-redox pathway). This pathway is dependent on oncogenic Kras and is absolutely essential for PDAC growth both in vitro and in vivo, while being dispensable in normal cells. Thus, there may be an accessible therapeutic window. We have shown that oncogenic Kras controls flux through the Gln-redox pathway by regulating the relative expression of two key metabolic enzymes; GOT1 and GLUD1, thereby promoting the transamination of Gln-derived aspartate by GOT1 and repressing the canonical conversion of glutamate to alpha-ketoglutarate by GLUD1. Ultimately, NADPH and pyruvate are produced by malic enzyme (ME1). Additionally, our data demonstrate that the overwhelming majority of Gln- derived pyruvate produced by ME1 is not converted to lactate via lactate dehydrogenase. Specifically the isotopomer analyses suggest that this pool of pyruvate is directly tunneled into the mitochondria where it can be acted upon by pyruvate carboxylase (PC). Together, this supports the idea that a complex exists between ME1, the mitochondrial pyruvate transporter (MPC1/2), and possibly PC. Consistent with this concept, we have shown that suppression of either MPC1 or PC results in a significant accumulation of fully labeled aspartate in Gln tracing studies, suggesting that the Gln-redox pathway has been inhibited. Against this backdrop, we propose a series of in-depth, mechanistic studies to elucidate: i) the regulation of the pathway by oncogenic Kras; ii) the integration of this pathway with other ROS scavenging pathways in PDAC; iii) the metabolic fate of the pyruvate end product, and iv) the impact of the PDAC microenvironment in vivo on this unique Gln metabolism. Given the difficulties in developing inhibitors to Kras, targeting Kras-regulated metabolic pathways that are required for growth may provide novel entry points of attack in this devastating cancer. Thus, a complete understanding of this novel Gln-redox pathway will be critical to translate these findings to the clinic. SA1. T explore the regulation of glutamine metabolism and redox balance by oncogenic Kras. SA2. To investigate the fate of malic enzyme derived pyruvate in PDAC glutamine metabolism. SA3. To explore how the PDAC microenvironment impacts glutamine metabolism and redox balance in vivo under basal and stress conditions.

Public Health Relevance

This proposal seeks to build on data from my laboratory showing that oncogenic Kras can reprogram glutamine metabolism in pancreatic cancer. Pancreatic cancer is highly lethal and current treatments such as chemotherapy and radiation are only minimally effective due to its profound therapeutic resistance. The results of these studies may have an important impact on the treatment of this disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Espey, Michael G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Lundquist, Mark R; Goncalves, Marcus D; Loughran, Ryan M et al. (2018) Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Mol Cell 70:531-544.e9
Biancur, Douglas E; Kimmelman, Alec C (2018) The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer 1870:67-75
Anglin, Justin; Zavareh, Reza Beheshti; Sander, Philipp N et al. (2018) Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorg Med Chem Lett 28:2675-2678
Yang, Annan; Herter-Sprie, Grit; Zhang, Haikuo et al. (2018) Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discov 8:276-287
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Biancur, Douglas E; Paulo, Joao A; Ma?achowska, Beata et al. (2017) Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun 8:15965
Lyssiotis, Costas A; Kimmelman, Alec C (2017) Metabolic Interactions in the Tumor Microenvironment. Trends Cell Biol 27:863-875
Sherman, Mara H; Yu, Ruth T; Tseng, Tiffany W et al. (2017) Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proc Natl Acad Sci U S A 114:1129-1134
Kimmelman, Alec C; White, Eileen (2017) Autophagy and Tumor Metabolism. Cell Metab 25:1037-1043
Sousa, Cristov√£o M; Biancur, Douglas E; Wang, Xiaoxu et al. (2016) Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536:479-83

Showing the most recent 10 out of 17 publications